Bristol Myers Squibb Shares Outstanding 2010-2022 | BMY

Bristol Myers Squibb shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Bristol Myers Squibb shares outstanding for the quarter ending September 30, 2022 were 2.148B, a 4.24% decline year-over-year.
  • Bristol Myers Squibb 2021 shares outstanding were 2.245B, a 0.58% decline from 2020.
  • Bristol Myers Squibb 2020 shares outstanding were 2.258B, a 31.89% increase from 2019.
  • Bristol Myers Squibb 2019 shares outstanding were 1.712B, a 4.58% increase from 2018.
Bristol Myers Squibb Annual Shares Outstanding
(Millions of Shares)
2021 2,245
2020 2,258
2019 1,712
2018 1,637
2017 1,652
2016 1,680
2015 1,679
2014 1,670
2013 1,662
2012 1,688
2011 1,717
2010 1,727
2009 1,978
Bristol Myers Squibb Quarterly Shares Outstanding
(Millions of Shares)
2022-09-30 2,148
2022-06-30 2,149
2022-03-31 2,164
2021-12-31 2,245
2021-09-30 2,243
2021-06-30 2,252
2021-03-31 2,265
2020-12-31 2,258
2020-09-30 2,290
2020-06-30 2,263
2020-03-31 2,258
2019-12-31 1,712
2019-09-30 1,634
2019-06-30 1,637
2019-03-31 1,637
2018-12-31 1,637
2018-09-30 1,636
2018-06-30 1,636
2018-03-31 1,640
2017-12-31 1,652
2017-09-30 1,645
2017-06-30 1,650
2017-03-31 1,671
2016-12-31 1,680
2016-09-30 1,679
2016-06-30 1,679
2016-03-31 1,680
2015-12-31 1,679
2015-09-30 1,678
2015-06-30 1,667
2015-03-31 1,676
2014-12-31 1,670
2014-09-30 1,670
2014-06-30 1,669
2014-03-31 1,666
2013-12-31 1,662
2013-09-30 1,662
2013-06-30 1,660
2013-03-31 1,655
2012-12-31 1,688
2012-09-30 1,666
2012-06-30 1,701
2012-03-31 1,706
2011-12-31 1,717
2011-09-30 1,715
2011-06-30 1,722
2011-03-31 1,714
2010-12-31 1,727
2010-09-30 1,726
2010-06-30 1,728
2010-03-31 1,725
2009-12-31 1,978
2009-09-30 1,984
2009-06-30 1,983
2009-03-31 1,981
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $155.188B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00